| Bioactivity | NNZ 2591 is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). NNZ 2591 shows orally active and cross the blood-brain barrier. NNZ 2591 shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. NNZ 2591 has the potential for the research of ischemic brain injury and angelman syndrome[1][2][3]. | ||||||||||||
| Name | NNZ 2591 | ||||||||||||
| CAS | 847952-38-9 | ||||||||||||
| Formula | C10H14N2O2 | ||||||||||||
| Molar Mass | 194.23 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|